| Literature DB >> 27167617 |
In-Woo Kim1,2, Joon Ha Lee1, Sathiyamoorthy Subramaniyam3, Eun-Young Yun1, Iksoo Kim2, Junhyung Park3, Jae Sam Hwang1.
Abstract
Cockroaches are surrogate hosts for microbes that cause many human diseases. In spite of their generally destructive nature, cockroaches have recently been found to harbor potentially beneficial and medically useful substances such as drugs and allergens. However, genomic information for the American cockroach (Periplaneta americana) is currently unavailable; therefore, transcriptome and gene expression profiling is needed as an important resource to better understand the fundamental biological mechanisms of this species, which would be particularly useful for the selection of novel antimicrobial peptides. Thus, we performed de novo transcriptome analysis of P. americana that were or were not immunized with Escherichia coli. Using an Illumina HiSeq sequencer, we generated a total of 9.5 Gb of sequences, which were assembled into 85,984 contigs and functionally annotated using Basic Local Alignment Search Tool (BLAST), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) database terms. Finally, using an in silico antimicrobial peptide prediction method, 86 antimicrobial peptide candidates were predicted from the transcriptome, and 21 of these peptides were experimentally validated for their antimicrobial activity against yeast and gram positive and -negative bacteria by a radial diffusion assay. Notably, 11 peptides showed strong antimicrobial activities against these organisms and displayed little or no cytotoxic effects in the hemolysis and cell viability assay. This work provides prerequisite baseline data for the identification and development of novel antimicrobial peptides, which is expected to provide a better understanding of the phenomenon of innate immunity in similar species.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27167617 PMCID: PMC4864078 DOI: 10.1371/journal.pone.0155304
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary of HiSeq and Assembly Statistics from E. coli-immunized and Non-immunized P. americana.
| Description | Samples | Reads | % | Bases | % | Avg. Length (bp) |
|---|---|---|---|---|---|---|
| Raw sequences | 1.TG1110R2526_l1( | 52,088,134 | 100.0 | 4,687,932,060 | 100 | 90.0 |
| 2.TG1110R2527_l1(non-immunized) | 53,131,048 | 100.0 | 4,781,794,320 | 100 | 90.0 | |
| Pre-Processed sequences | 1.TG1110R2526_l1( | 49,317,908 | 94.6 | 4,302,302,163 | 91.77 | 82.5 |
| 2.TG1110R2527_l1(non-immunized) | 50,270,016 | 94.6 | 4,380,901,481 | 91.62 | 82.5 | |
| Contig | 85,984 | 53,382,468 | 620.8 | |||
| Repeat mask | Contigs_Masked | 85,608 | 44,222,145 | 516.6 |
Fig 1Overview of the P. americana Annotation.
(A) Comparison of sequence length distribution before (blue) and after (red) annotation. (B) Top-hit species distribution of BLAST matches of sequences unique to P. americana.
Summary Statistics of Gene Ontology Categories.
| Groups | Category | Contigs (%) | |
| A. BLAST | Total contigs | 85,608 (100) | |
| Has UniProt ID | 17,744 (20.7) | ||
| Unique UniProt ID | 13,726 (16.0) | ||
| Category | # Up (%) | # Down (%) | |
| B. Digital Gene Expression | Fold change ≥ 2 | 848 (1.0) | 1,228 (1.4) |
| Known UniProt ID | 232 (0.3) | 448 (0.5) | |
| Unique UniProt ID | 218 (0.3) | 373 (0.4) | |
| Category | # Term | # Contigs (%) | |
| C. Gene Ontology | Biological Process | 4,953 | 11,395 (13.3) |
| Molecular Function | 2,712 | 11,822 (13.8) | |
| Cellular Component | 947 | 10,958 (12.8) | |
Fig 2Gene Ontology (GO) Classification of the P. americana Transcriptome.
The histogram of the GO annotation was generated automatically using the web histogram tool WEGO (http://wego.genomics.org.cn/cgi-bin/wego/index.pl) based on the most recent GO archive available. The results are summarized into three main GO categories: cellular component, molecular function, and biological process. The right y-axis indicates the number of genes in a category. The left y-axis indicates the percentage of a specific category of genes in that main category. One gene could be annotated into more than one GO term.
In Silico Functional Characterization of Selected Antimicrobial Peptides (AMPs).
| Program | Parameter | Filtered | |
|---|---|---|---|
| PEPSTATS | Length | ≤ 50mer | 18,309 |
| Charge | >0(+) | 64,172 | |
| pI | 8 ≤ pI ≤ 12 | 51,872 | |
| AMPA | Stretch No. | ≥1 | 45,751 |
| Known AMP | BLASTP (E-value) | 1.00E-05 | 83,350 (42) |
| PATMATCH | No mismatch | 30 | |
| CAMP | AMP (Discriminant analysis) | TRUE (score < -0.251) | 30,534 |
| AMP (SVM) | TRUE (no score) | 26,948 | |
| TANGO | AGG | AGG ≤ 500 | 37,092 |
| HELIX | 0 ≤ HELIX ≤ 25 | 38,526 | |
| BETA | 25 ≤ BETA ≤ 100 | 3,711 | |
| AGGRESCAN | Na4vSS | -40 ≤ Na4vSS ≤ 60 | 81,166 |
| EPESTFIND | Protein cleavage site | FALSE | 40,791 |
| Expression change | NC or Increased | -1 < log2 (FC) | 64,725 |
| Final filtered AMPs | 86 | ||
pI, isoelectric point; SVM, support vector machine; NC, no change; FC, fold change.
List of Predicted Antimicrobial Peptides (AMPs) from American Cockroach Transcripts.
| Sequence ID | Length | Discriminant | log2(FC) | Sequence | SVM-score | Prediction |
|---|---|---|---|---|---|---|
| ISGCock_Contig04_0915 | 50 | AMP | 3.07 | ALQICTRNMIDDRLPYVADNVRP | -1.01 | non-allergen |
| ISGCock_Contig02_3734 | 44 | AMP | 2.96 | KLHEFKLGYPLATNYACAIARDL | -1.04 | non-allergen |
| ISGCock_Contig14_1231 | 41 | AMP | 2.57 | ISYFLFLDFRDIFHSQRRKVNFNAG | -1.02 | non-allergen |
| ISGCock_Contig13_3331 | 47 | AMP | 2.55 | I | -1.00 | non-allergen |
| ISGCock_Contig13_4610–1 | 44 | AMP | 2.55 | HL | -0.97 | non-allergen |
| ISGCock_Contig13_4610–2 | 44 | AMP | 2.55 | HLYPCKLNLKLGKVPFHFLNLNHKGKSIMV | -0.97 | non-allergen |
| ISGCock_Contig01_3774 | 31 | AMP | 2.31 | PPHMQSPLCAP | -1.00 | non-allergen |
| ISGCock_Contig12_2253 | 23 | AMP | 2.31 | KQRKEGEC | -1.00 | non-allergen |
| ISGCock_Contig13_4305 | 36 | AMP | 2.29 | YAHLSNIP | -1.02 | non-allergen |
| ISGCock_Contig16_2060 | 34 | AMP | 2.29 | ISHNHLTA | -1.04 | non-allergen |
| ISGCock_Contig13_2121 | 31 | AMP | 2.27 | LSPHSSNVKRKEHL | -0.99 | non-allergen |
| ISGCock_Contig11_1401 | 41 | AMP | 2.01 | R | -0.96 | non-allergen |
| ISGCock_Contig16_4974 | 44 | AMP | 1.99 | R | -1.00 | non-allergen |
| ISGCock_Contig07_3736–1 | 31 | AMP | 1.88 | C | -1.02 | non-allergen |
| ISGCock_Contig07_3736–2 | 31 | AMP | 1.88 | CNYISFFRKCKNSQSTMY | -1.02 | non-allergen |
| ISGCock_Contig14_0122 | 26 | AMP | 1.70 | S | -1.01 | non-allergen |
| ISGCock_Contig05_0163 | 35 | AMP | 1.66 | KSILYLLCRDFRDLHKYAAL | -1.00 | non-allergen |
| ISGCock_Contig10_4736–1 | 37 | AMP | 1.57 | LM | -0.77 | non-allergen |
| ISGCock_Contig10_4736–2 | 37 | AMP | 1.57 | LMLCKGFLRHSYKSIHER | -0.77 | non-allergen |
| ISGCock_Contig07_2123 | 19 | AMP | 1.55 | N | -1.01 | non-allergen |
| ISGCock_Contig13_3006 | 47 | AMP | 1.49 | ANL | -1.00 | non-allergen |
| ISGCock_Contig05_0593 | 18 | AMP | 1.48 | -1.01 | non-allergen | |
| ISGCock_Contig12_4176 | 30 | AMP | 1.38 | V | -1.06 | non-allergen |
| ISGCock_Contig15_1337–1 | 46 | AMP | 1.31 | K | -1.00 | non-allergen |
| ISGCock_Contig15_1337–2 | 46 | AMP | 1.31 | KRMKLNAKKLSFCDHLNSYLNLSPTLFI | -1.00 | non-allergen |
The underlined peptide sequences were synthesized according to results of the AMPA stretches.
Fig 3Radial Diffusion Assay.
Antimicrobial activities of 11 selected peptides against E. coli, S. aureus, and C. albicans determined by a radial diffusion assay. Peptide concentration (x-axis) was plotted against the diameter of the microbial growth inhibition zone (y-axis) after incubation for 12 h, and is expressed in units (1 mm = 10 units). Melittin was used as a positive control. Mean values were obtained from tests repeated three times.
Minimum Inhibitory Concentration (MIC, μg/mL) for Antimicrobial Activity of the Selected Peptides and Melittin.
| Melittin | 8 | 4 | 8 |
| ISGCock_Contig04_0915 | 64 | >64 | >64 |
| ISGCock_Contig13_4610–1 | 64 | >64 | >64 |
| ISGCock_Contig16_2060 | 16 | 16 | 16 |
| ISGCock_Contig16_4974 | 16 | 16 | 16 |
| ISGCock_Contig07_3736–1 | >64 | >64 | >64 |
| ISGCock_Contig10_4736–2 | 16 | >64 | 32 |
| ISGCock_Contig13_3006 | 64 | >64 | 64 |
| ISGCock_Contig05_0593 | 4 | 16 | 4 |
| ISGCock_Contig12_4176 | 8 | >64 | 8 |
| ISGCock_Contig15_1337–1 | >64 | >64 | 16 |
| ISGCock_Contig15_1337–2 | >64 | >64 | 64 |
Fig 4Cytotoxic Effects of 11 Selected Peptides.
(A) Hemolytic activity of the peptides. Peptide concentration (x-axis) is plotted against the percentage of hemolysis (y-axis) of rat red blood cells after incubation for 30 min. Melittin was used as the positive control. The percent hemolysis was calculated with the following equation: hemolysis (%) = (A540 of sample − A540 of peptide-free control)/(A540 of 100% control − A540 of peptide-free control) × 100. (B) Cell viability of human keratinocytes and human umbilical vein endothelial cells (HUVECs) after peptides treatment. Cell viability was measured by an MTS assay after a 24-h incubation with the indicated amounts of each peptide. Each symbol represents the mean value estimated from triplicate experiments.